254 related articles for article (PubMed ID: 31587155)
1. Ubiquitin-Specific Protease 22/Silent Information Regulator 1 Axis Plays a Pivotal Role in the Prognosis and 5-Fluorouracil Resistance in Hepatocellular Carcinoma.
Wen X; Ling S; Wu W; Shan Q; Liu P; Wang C; Wei X; Ding W; Teng X; Xu X
Dig Dis Sci; 2020 Apr; 65(4):1064-1073. PubMed ID: 31587155
[TBL] [Abstract][Full Text] [Related]
2. USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway.
Ling S; Li J; Shan Q; Dai H; Lu D; Wen X; Song P; Xie H; Zhou L; Liu J; Xu X; Zheng S
Mol Oncol; 2017 Jun; 11(6):682-695. PubMed ID: 28417539
[TBL] [Abstract][Full Text] [Related]
3. USP22 knockdown enhanced chemosensitivity of hepatocellular carcinoma cells to 5-Fu by up-regulation of Smad4 and suppression of Akt.
Zhang J; Luo N; Tian Y; Li J; Yang X; Yin H; Xiao C; Sheng J; Li Y; Tang B; Li R
Oncotarget; 2017 Apr; 8(15):24728-24740. PubMed ID: 28445968
[TBL] [Abstract][Full Text] [Related]
4. LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells.
Xiong H; Ni Z; He J; Jiang S; Li X; He J; Gong W; Zheng L; Chen S; Li B; Zhang N; Lyu X; Huang G; Chen B; Zhang Y; He F
Oncogene; 2017 Jun; 36(25):3528-3540. PubMed ID: 28166203
[TBL] [Abstract][Full Text] [Related]
5. MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells.
Ke M; Dong J; Wang Y; Zhang J; Zhang M; Wu Z; Lv Y; Wu R
Int J Biochem Cell Biol; 2018 Aug; 101():39-48. PubMed ID: 29800725
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of anti-tumor effects of 5-fluorouracil on hepatocellular carcinoma by low-intensity ultrasound.
Hu Z; Lv G; Li Y; Li E; Li H; Zhou Q; Yang B; Cao W
J Exp Clin Cancer Res; 2016 Apr; 35():71. PubMed ID: 27102814
[TBL] [Abstract][Full Text] [Related]
7. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.
Chen HC; Jeng YM; Yuan RH; Hsu HC; Chen YL
Ann Surg Oncol; 2012 Jun; 19(6):2011-9. PubMed ID: 22146883
[TBL] [Abstract][Full Text] [Related]
8. Expression of USP22 and Survivin is an indicator of malignant behavior in hepatocellular carcinoma.
Tang B; Liang X; Tang F; Zhang J; Zeng S; Jin S; Zhou L; Kudo Y; Qi G
Int J Oncol; 2015 Dec; 47(6):2208-16. PubMed ID: 26497847
[TBL] [Abstract][Full Text] [Related]
9. Loss of Runt-related transcription factor 3 induces resistance to 5-fluorouracil and cisplatin in hepatocellular carcinoma.
Kataoka J; Shiraha H; Horiguchi S; Sawahara H; Uchida D; Nagahara T; Iwamuro M; Morimoto H; Takeuchi Y; Kuwaki K; Onishi H; Nakamura S; Takaki A; Nouso K; Yagi T; Yamamoto K; Okada H
Oncol Rep; 2016 May; 35(5):2576-82. PubMed ID: 26985715
[TBL] [Abstract][Full Text] [Related]
10. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells.
Chen Z; Ma T; Huang C; Zhang L; Lv X; Xu T; Hu T; Li J
Cell Signal; 2013 Dec; 25(12):2693-701. PubMed ID: 24018051
[TBL] [Abstract][Full Text] [Related]
11. USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1α/USP22 positive feedback loop upon TP53 inactivation.
Ling S; Shan Q; Zhan Q; Ye Q; Liu P; Xu S; He X; Ma J; Xiang J; Jiang G; Wen X; Feng Z; Wu Y; Feng T; Xu L; Chen K; Zhang X; Wei R; Zhang C; Cen B; Xie H; Song P; Liu J; Zheng S; Xu X
Gut; 2020 Jul; 69(7):1322-1334. PubMed ID: 31776228
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma.
Wang H; Jiang H; Zhou M; Xu Z; Liu S; Shi B; Yao X; Yao M; Gu J; Li Z
Cancer Lett; 2009 Jun; 279(1):30-8. PubMed ID: 19217205
[TBL] [Abstract][Full Text] [Related]
13. USP22-JMJD8 axis promotes Lenvatinib resistance in hepatocellular carcinoma.
Guo J; Zhao J
Biochim Biophys Acta Mol Cell Res; 2024 Jan; 1871(1):119617. PubMed ID: 37898375
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance.
Chang YS; Su CW; Chen SC; Chen YY; Liang YJ; Wu JC
Cells; 2022 Feb; 11(4):. PubMed ID: 35203285
[TBL] [Abstract][Full Text] [Related]
15. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
[TBL] [Abstract][Full Text] [Related]
16. Identification of the genes chemosensitizing hepatocellular carcinoma cells to interferon-α/5-fluorouracil and their clinical significance.
Sakabe T; Tsuchiya H; Kanki K; Azumi J; Gonda K; Mizuta Y; Yamada D; Wada H; Shomori K; Nagano H; Shiota G
PLoS One; 2013; 8(2):e56197. PubMed ID: 23457527
[TBL] [Abstract][Full Text] [Related]
17. Caffeine enhances the anti-tumor effect of 5-fluorouracil via increasing the production of reactive oxygen species in hepatocellular carcinoma.
Wang Z; Gu C; Wang X; Lang Y; Wu Y; Wu X; Zhu X; Wang K; Yang H
Med Oncol; 2019 Oct; 36(12):97. PubMed ID: 31664534
[TBL] [Abstract][Full Text] [Related]
18. Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line.
Gu W; Fang FF; Li B; Cheng BB; Ling CQ
Asian Pac J Cancer Prev; 2012; 13(9):4807-14. PubMed ID: 23167424
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma.
Wang Y; Zhu Q; Hu H; Zhu H; Yang B; He Q; Yu L; Zeng S
Biochem Pharmacol; 2021 Jun; 188():114546. PubMed ID: 33838133
[TBL] [Abstract][Full Text] [Related]
20. RBFOX3 Regulates the Chemosensitivity of Cancer Cells to 5-Fluorouracil via the PI3K/AKT, EMT and Cytochrome-C/Caspase Pathways.
Liu T; Wu X; Li Y; Lu W; Zheng F; Zhang C; Long Q; Qiu H; Li Y; Ge Q; Chen M; Yu X; Chen W; Zhang H; Huang W; Luo M; Deng W; Li L
Cell Physiol Biochem; 2018; 46(4):1365-1380. PubMed ID: 29689552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
